TY  - JOUR
AU  - Fraunberger, Peter
AU  - Gröne, Elisabeth
AU  - Gröne, Hermann-Josef
AU  - Drexel, Heinz
AU  - Walli, Autar K
TI  - Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.
JO  - Journal of Inflammation
VL  - 14
IS  - 1
SN  - 1476-9255
CY  - London
PB  - BioMed Central
M1  - DKFZ-2017-00953
SP  - 3
PY  - 2017
AB  - Statins (HMG CoA reductase inhibitors), in addition to reducing circulating cholesterol and incidence of coronary heart disease, also have pleiotropic, anti-inflammatory effects. Patients with chronic liver diseases, non-alcoholic fatty liver disease (NAFLD) or hepatitis C are often excluded from statin therapy because of adverse effects in a small cohort of patients despite increased cardiovascular risk cholesterol. Ezetimibe, which inhibits cholesterol absorption by inhibition of Niemann-Pick C1 like 1 (NPC1L1) protein in the brush border of intestinal cells, has been suggested as a new therapeutic option in these patients.Effects of ezetimibe on lipoprotein metabolism, hepatic and intestinal lipid content in guinea pigs, an animal model with a lipoprotein profile and pattern similar to humans were investigated. In order to investigate a possible effect of ezetimibe on cholesterol induced inflammation NF-kappaB activation as an indicator for inflammatory processes in liver and gut tissue was measured.Lipid enriched diet led to accumulation of lipids in hepatic tissue which caused strong hepatic NF-kappaB activation. Ezetimibe reduced lipid diet induced increase of circulating cholesterol by about 77
LB  - PUB:(DE-HGF)16
C6  - pmid:28167864
C2  - pmc:PMC5288872
DO  - DOI:10.1186/s12950-017-0150-y
UR  - https://inrepo02.dkfz.de/record/120524
ER  -